GCC 0429 - An Umbrella Protocol for Collection of Blood and Leukapheresis Products from Normal Subjects and Saliva, Blood and Bone Marrow, Pleural, Ascitic or Pericardial Fluid, and/or Tumor Tissue Samples from Patients With Malignancies to be Used in Laboratory Research
GCC 0548 - A Phase 1 Study of AFP464 (Aminoflavone Prodrug) In Patients with Advanced Solid Tumors
GCC 0558 - A Phase 1, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients with Varying Degrees of Renal Function
GCC 0651 - A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients with Advanced Solid Tumors
GCC 0737 - A Multicenter, Open-Label, Noncomparative Phase 1 Clinical and Pharmacokinetic Study of Oral Tak-285 in Patients with Advanced Cancer
GCC0629 - A Phase I, Open-Label, Multicenter, Dose-Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination with Weekly Standard Dose Gemcitabine in Patients with Advanced Solid Malignancies
GCC0643 - A Phase 1 Study of EC0225 Administered Weeks 1 and 2 of a Four-Week Cycle
GCC0715 - A Phase I Safety and Pharmacokinetic Study of ARRY-520 in Solid Tumors
GCC0768 - Phase 1B/2, Multicenter, Open-Label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
GCC0782 - A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
GCC0802 - A Multicenter, Open-Label, Phase I Study of Single-Agent GMX1777 Administered Every 3 Weeks to Patients With Refractory Solid Tumors, Lymphomas, Chronic Lymphocytic Leukemia, or Multiple Myeloma
GCC0803 - A Phase 1 Study of EC0489 Administered Weeks 1 and 3 Of A 4-Week Cycle
GCC0913 - Open-Label, Sequential, Ascending, Multi-Dose, Phase 1 Study of KW-2450 as Monotherapy in Subjects with Previously Treated Advanced Solid Tumor
Email this Page
Print this Page
